Home | About us | Editorial board | Search | Ahead of print | Current issue | Archives | Submit article | Instructions | Subscribe | Contacts | Advertise | Login 
Search Article 
Advanced search 
  Users Online: 560 Home Print this page Email this page Small font sizeDefault font sizeIncrease font size  
Year : 2013  |  Volume : 17  |  Issue : 2  |  Page : 254-259

Lean body mass-based levothyroxine replacement in young athyrotic patients with differentiated carcinoma of thyroid

1 Institute of Nuclear Medicine and Ultrasound, BAEC, BSMMU Campus, Shahbag, Dhaka, Bangladesh
2 Department of Cardiology, Bangabandhu Sheikh Mujib Medical University (BSMMU, Dhaka), Shahbag, Dhaka, Bangladesh
3 Bangladesh Atomic Energy Commission, E 12/A, Agargaon, Sher e Bangla Nagar, Dhaka, Bangladesh
4 Department of Pathology, Sir Salimullah Medical College and Mitford Hospital, Dhaka, Bangladesh
5 Department of Physics, Bangladesh University of Engineering and Technology, Dhaka, Bangladesh

Correspondence Address:
Fatima Begum
Institute of Nuclear Medicine and Ultrasound, BAEC, Bangabandhu Sheikh Mujib Medical University Campus, Shahbag, Dhaka
Login to access the Email id

Source of Support: This research work was approved and funded by Committee for Advanced Studies and Research (CASR) of Bangladesh University of Engineering and Technology (BUET), No: DAERS/CASR/R- 01/2008/D-1321/114,, Conflict of Interest: None

DOI: 10.4103/2230-8210.109697

Rights and Permissions

Objective: The objective of this study was to optimize dose of levothyroxine (LT4) based on lean body mass (LBM) in young athyrotic patients with differentiated carcinoma of thyroid (DCT) which has not been properly addressed in Bangladesh before. Materials and Methods: Sixty patients with DCT (age, range: 20-39 years) having total thyroidectomy followed by radioiodine ablative therapy (RIT) and 23 euthyroid volunteers were recruited. Clinical, biochemical parameters were obtained from all patients after 2 months of RIT and on LT4 replacement at a dose of 200 μg/day as first follow up visit and also from control subjects. Then 60 patients were divided into two groups consisting of 30 patients each. Patients of Group-I received LT4 replacement based on LBM measured by dual energy X-ray absorptiometry (DXA) and Group-II continued LT4 replacement in conventional dose. Patients of both groups were assessed again for same parameters at 6 to 12 months at the second visit. Results: Optimized dose of LT4 based on LBM by DXA (131 ±23 μg/day) significantly reduced thyroid hormones and kept thyroid stimulating hormone (TSH) in expected levels in patients of Group-I at the second visit compared to patients of Group-II who continued conventional LT4 dose (200 μg/day). Hyperthyroid symptom scale (HSS) was significantly reduced to 2 ± 1 in patients of Group-I but not in patients of Group-II, HSS, 8 ±1 ( P < 0.001). Conclusion: Optimization of LT4 dose based on LBM can avoid chronic exposure of mild excess of thyroid hormone in young patients with low risk DCT.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded260    
    Comments [Add]    

Recommend this journal